Clinical Trials Logo

Carcinoma, Hepatocellular clinical trials

View clinical trials related to Carcinoma, Hepatocellular.

Filter by:

NCT ID: NCT03586973 Completed - Clinical trials for Advanced Hepatocellular Carcinoma

A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular Carcinoma

Start date: August 6, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of cabozantinib in Japanese participants with advanced hepatocellular carcinoma (HCC) who have received prior systemic anticancer therapy.

NCT ID: NCT03586050 Completed - Clinical trials for Hepatocellular Carcinoma

Study to Evaluate the Safety and Effectiveness of Microwave Ablation in Patients With Hepatocellular Carcinoma in Korea

Start date: December 11, 2017
Phase: N/A
Study type: Interventional

This is a single arm, non-randomized, single center study to evaluate ablation, oncologic outcomes and safety in the treatment of hepatocellular carcinoma.

NCT ID: NCT03578874 Completed - Clinical trials for Hepatocellular Carcinoma

SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC

Start date: June 20, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the resectability after treatment with SECOX (sorafenib, capecitabine, oxaliplatin) as neoadjuvant therapy in patients with locally advanced hepatocellular carcinoma

NCT ID: NCT03575806 Completed - Clinical trials for Hepatocellular Carcinoma

Combine TACE and Autologous Tcm Immunotherapy Versus TACE Alone for HCC With MVI After Radical Resection

Start date: January 9, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of combining autologous Tcm immunotherapy and TACE in HCC patients with MVI after radical resection. Patients will be assigned either to the experimental arm to receive autologous Tcm immunotherapy and TACE or to the active comparator (TACE alone).

NCT ID: NCT03572582 Completed - Clinical trials for Carcinoma, Hepatocellular

Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma

IMMUTACE
Start date: June 14, 2018
Phase: Phase 2
Study type: Interventional

The IMMUTACE study evaluates the safety and the efficacy of the anti-programmed-death-1 antibody (anti-PD-1) nivolumab in combination with transarterial chemoembolization (TACE) in patients with multinodular, intermediate stage hepatocellular carcinoma (HCC) as first line therapy.

NCT ID: NCT03564405 Completed - Clinical trials for Hepatocellular Carcinoma Non-resectable

Pilot Clinical Trial to Evaluate the UNI-DEB for Unresectable Hepatocellular Carcinoma

Start date: December 5, 2016
Phase: N/A
Study type: Interventional

Pilot Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma

NCT ID: NCT03535259 Completed - Clinical trials for Hepatocellular Carcinoma, Radiotherapy, Sorafenib

Phase II Study of Concurrent Sorafenib and Intensity-modulated Radiotherapy (IMRT) for Advanced Hepatocellular Carcinoma

SIRAHCC
Start date: May 8, 2018
Phase: Phase 2
Study type: Interventional

This is a single-arm phase II clinical trial to investigate the efficacy and toxicity of concurrent sorafenib and intensity-modulated radiotherapy (IMRT) for advanced hepatocellular carcinoma with portal vein or hepatic vein tumor thrombosis or lymph node involved. Eligibility patients will receive IMRT to hepatic primary tumor, vein tumor thrombosis, and metastasis lymph node with concurrently sorafenib with a dose of 400mg twice daily. Prescription of IMRT will be a conventional fraction dose of 2Gy to a total dose of 40 to 60Gy. Sorafenib will be maintained with a dose of 400mg twice daily after IMRT until disease progression, or unacceptable adverse events. Six months of sorafenib maintenance is recommended.

NCT ID: NCT03534843 Completed - Clinical trials for Hepatocellular Carcinoma

A Comparison Between Child-Pugh and Albumin-Bilirubin Scores

Start date: January 1, 2005
Phase:
Study type: Observational

To compare Child-Pugh and Albumin-Bilirubin scores in patients with spontaneous rupture of hepatocellular carcinoma

NCT ID: NCT03533920 Completed - Clinical trials for Hepatocellular Carcinoma Non-resectable

Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma

Start date: October 25, 2017
Phase: N/A
Study type: Interventional

Pivotal Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma

NCT ID: NCT03516890 Completed - Clinical trials for Hepatocellular Carcinoma

Management of Spontaneous Ruptured Hepatocellular Carcinoma

Start date: January 1, 2005
Phase:
Study type: Observational

To investigate the best treatment for hepatocellular carcinoma rupture